Quantcast

IBD: Exposure to anti-TNF agents in utero: controlling health risks

Research paper by C. Janneke van der Woude, Shannon L. Kanis

Indexed on: 05 Jun '16Published on: 02 Jun '16Published in: Nature Reviews Gastroenterology and Hepatology



Abstract

A recent study reports on drug clearance in newborn babies after in utero exposure to anti-TNF antibodies, infliximab and adalimumab. As women with IBD are increasingly exposed to these drugs due to changing treatment paradigms and earlier diagnosis, this commentary explores these clinically important results.